Anti-PD-1 humanized monoclonal antibody and application thereof

A monoclonal antibody, PD-1 technology, applied in the field of molecular immunology, can solve the problem of low affinity

Active Publication Date: 2015-12-23
ANHUI RUBIOX VISION BIOTECH
View PDF4 Cites 52 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently existing PD-1 antibody drugs have low affin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-PD-1 humanized monoclonal antibody and application thereof
  • Anti-PD-1 humanized monoclonal antibody and application thereof
  • Anti-PD-1 humanized monoclonal antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The preparation of embodiment 1PD-1 antigen

[0033] The cDNA of human PD-1 was synthesized from Nanjing GenScript Company, the GeneID is 5133, and the cDNAID is NM_005018.2. Human IgG1Fc tag was added after the synthetic extracellular region PD-1 gene, and two restriction enzyme sites of XbaI and BamHI were introduced at both ends to connect to the pTT5 expression plasmid, which was verified to be correct by sequencing. The sequenced plasmid was transfected into Trans10 (purchased from Beijing Quanshijin Biotechnology Co., Ltd.), and a single clone was picked and inoculated into 1 liter of LB liquid medium until OD 600 When the temperature is 1, the bacteria are collected by centrifugation, and the plasmid is extracted with a large plasmid extraction kit (purchased from Qiagen).

[0034] The correct expression vector identified by sequencing was transfected into 293F cells (purchased from Invitrogen), cultured at 37°C, 5% CO2, and 130 rpm / min for 7 days, and the super...

Embodiment 2

[0035] Example 2 Expression and purification of PD-1 antibody AbB7 / AbB8

[0036] The cDNA of the light chain of the artificially synthesized antibody AbB7 (its sequence is shown in SEQ ID NO.1), the cDNA of the artificially synthesized antibody AbB7 heavy chain (its sequence is shown in SEQ ID NO.3), the cDNA of the artificially synthesized antibody AbB8 heavy chain (its sequence As shown in SEQ ID NO.5), the synthesized cDNAs were respectively cloned into pTT5 plasmids, and the correct construction of the plasmids was confirmed by sequencing.

[0037] Co-transfect the correct AbB7 / AbB8 heavy chain expression vector and light chain expression vector (1:1) identified by sequencing into 293F cells at 37 degrees, 5% CO 2After culturing at 130rpm / min for 7 days, the supernatant was collected by centrifugation. Centrifuge the supernatant at 4000rpm for 10min, and filter it with a 0.45μm filter membrane to collect the filtrate; add 400mM NaCl to the filtrate; adjust the pH to 8.0. ...

Embodiment 3

[0038] Example 3 Determination of affinity Kd of PD-1 humanized antibody AbB7 / AbB8 by SPR method

[0039] The characterization affinity and binding kinetics of anti-PD-1 antibodies AbB7 and / AbB8 were analyzed by Biacore3000 instrument (purchased from GE). The recombinant human PD1 extracellular region protein was covalently coupled with biotin using a biotin-labeling kit (Pierce), and then flowed through an avidin-labeled SA chip (purchased from GE), so that the reaction value RU reached about 450 . Binding was measured by flowing antibodies in PBS buffer at concentrations of 0.0133, 0.0266, 0.0532, 0.1064, 0.2128 μM and a flow rate of 50 μl / min. Antigen-antibody binding kinetics were followed for 3 minutes and dissociation kinetics were followed for 10 minutes. Association and dissociation curves were fitted to a 1:1 Langmuir binding model using BIAevaluation software. In order to minimize the role of avidity in estimating the binding constant, only the initial data segmen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an anti-PD-1 humanized monoclonal antibody and application thereof, belonging to the technical field of molecular immunology. The anti-PD-1 humanized monoclonal antibody provided by the invention contains a light chain and a heavy chain, wherein the amino acid sequence of the light chain is as shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain is as shown in SEQ ID NO.4 or SEQ ID NO.6. Meanwhile, the invention also provides a nucleotide sequence coding the light chain and heavy chain. The anti-PD-1 humanized monoclonal antibody provided by the invention has very high affinity with human PD-1 protein, and can interdict PD-1/PD-L1 combination so as to promote T cell proliferation and IFN-gamma secretion.

Description

technical field [0001] The invention relates to an anti-PD-1 humanized monoclonal antibody and its application, belonging to the technical field of molecular immunology. Background technique [0002] PD-1, also known as programmed death receptor 1, is a member of the CD28 superfamily, which was originally cloned from the apoptotic mouse T cell hybridoma 2B4.11, and was discovered by Professor Honjosuke of Kyoto University in 1992 . PD-1 protein is expressed in activated T cells, B cells, etc. [0003] PD-1 receptor PD-L1, also known as programmed cell death-ligand 1 or surface antigen differentiation cluster 274 (clusterofdifferentiation274, CD274) or B7 homolog (B7homolog1, B7-H1), is a protein in the human body , encoded by the CD274 gene. PD-L1 is a type 1 transmembrane protein with a size of 40 kDa, which is believed to be involved in the suppression of the immune system under certain conditions such as pregnancy, tissue transplantation, autoimmune diseases, and certa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28C12N15/13A61K39/395A61P35/00
Inventor 汪国兴胡思怡袁红武婷
Owner ANHUI RUBIOX VISION BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap